- Home
- DIAX vs CGEM Comparison
DIAX vs CGEM Comparison
Compare DIAX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- CGEM
- Stock Information
- Founded
- DIAX 2005
- CGEM 2016
- Country
- DIAX United States
- CGEM United States
- Employees
- DIAX N/A
- CGEM N/A
- Industry
- DIAX Finance Companies
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- DIAX Finance
- CGEM Health Care
- Exchange
- DIAX Nasdaq
- CGEM Nasdaq
- Market Cap
- DIAX 539.0M
- CGEM 506.1M
- IPO Year
- DIAX N/A
- CGEM 2021
- Fundamental
- Price
- DIAX $13.50
- CGEM $7.89
- Analyst Decision
- DIAX
- CGEM Strong Buy
- Analyst Count
- DIAX 0
- CGEM 7
- Target Price
- DIAX N/A
- CGEM $32.86
- AVG Volume (30 Days)
- DIAX 96.6K
- CGEM 520.6K
- Earning Date
- DIAX 01-01-0001
- CGEM 05-14-2025
- Dividend Yield
- DIAX 7.93%
- CGEM N/A
- EPS Growth
- DIAX N/A
- CGEM N/A
- EPS
- DIAX N/A
- CGEM N/A
- Revenue
- DIAX N/A
- CGEM N/A
- Revenue This Year
- DIAX N/A
- CGEM N/A
- Revenue Next Year
- DIAX N/A
- CGEM N/A
- P/E Ratio
- DIAX N/A
- CGEM N/A
- Revenue Growth
- DIAX N/A
- CGEM N/A
- 52 Week Low
- DIAX $12.80
- CGEM $6.85
- 52 Week High
- DIAX $15.12
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- DIAX 40.84
- CGEM 47.24
- Support Level
- DIAX $12.66
- CGEM $6.93
- Resistance Level
- DIAX $14.03
- CGEM $8.10
- Average True Range (ATR)
- DIAX 0.44
- CGEM 0.52
- MACD
- DIAX 0.02
- CGEM 0.07
- Stochastic Oscillator
- DIAX 50.70
- CGEM 83.20
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.